A study combining two drugs, Daratumumab and Lenalidomide as Maintenance Therapy for
Patients with Multiple Myeloma
Does treating multiple myeloma patients with two drugs Daratumumab and Lenalidomide
help them become negative for the disease?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Patients will be treated with Daratumumab and Lenalidomide or Lenalidomide alone for
two years and then tested for minimal residual disease. Minimal residual disease
is the evidence for the presence of residual malignant cells, even when so few cancer
cells are present that they cannot be found by routine means. In a patient who has
been treated, the detection of MRD indicates that treatment is incomplete. MRD can
thus distinguish who needs intensive and potentially more toxic therapy from those
who do not. After 2 years of Maintenance, MRD is assessed to guide further therapy.
MRD-positive patients will continue with the assigned treatment. MRD-negative patients
will be either continue or discontinue the assigned treatment. Patients are treated
for up to 7 years and followed for up to 15 years.
Study Reference #: CMMY19113
Lead Researcher (Principal Investigator)
Lead Researcher: Brea Lipe
Study Contact InformationStudy Coordinator: Kaitlyn Burrows
Phone: (585) 275-5150
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search